Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

DISEASE CHARACTERISTICS: * Diagnosis of chronic myelogenous leukemia (CML) documented by cytogenetic and molecular analyses at Johns Hopkins * Philadelphia chromosome (Ph)-positive or -negative CML * Ph-negative CML allowed with presence of either: * BCR-ABL rearrangement (on molecular, fluorescent in situ hybridization, or polymerase chain reaction analyses) * p210 protein * One of the following: * Patient age 18 to 65 * Disease duration longer than 3 years * Accelerated phase CML * Accelerated phase diagnosis based on any of the following: * More than 10% to less than 30% blasts in blood or bone marrow * No hematologic response to prior conventional therapy (hydroxyurea or interferon) * Extramedullary disease (e.g., progressive splenomegaly or lymphadenopathy) * Basophilia greater than 10% in blood or bone marrow * Other cytogenetic abnormalities in addition to a single Ph chromosome * Second chronic phase * Failure on interferon suggested of patients over age 18 with chronic phase CML, with failure defined as: * No detectable Ph-negative metaphases in marrow after 6 months * No progressive increase in Ph-negative metaphases in marrow after 6-12 months * Less than 50% Ph-negative metaphases after 1 year * No complete cytogenetic remission after 2 years * Intolerance to interferon therapy * No blast crisis CML, chronic myelomonocytic leukemia, or juvenile CML * The following conditions are allowed: * Leukocyte count abnormalities * Fibrosis * Anemia * Fever or bone pain * Thrombocytopenia * Bone marrow reticulin * Availability of an HLA-identical sibling donor * At least 3 years of age (priority given to donors over age 10) * Priority given to CMV-negative donor if patient CMV-negative * No medical or psychiatric condition that precludes transplant procedure PATIENT CHARACTERISTICS: Age * 18 to 65 Performance status * ECOG 0-1 Life expectancy * Not specified Hematopoietic * See Disease Characteristics Hepatic * Not specified Renal * Not specified Other * No history of intolerance to sargramostim (GM-CSF) PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics Chemotherapy * See Disease Characteristics Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified